ALTUVIIIO®
(efanesoctocog alfa)
SANOFI
HK Reg. No. HK-68400, HK-68401 (10 Oct, 2024)
Composition: 2
• Available as a white to off-white lyophilized powder for reconstitution in single dose vials containing nominally 500 or 3000 international units (IU) per vial
• A prefilled diluent syringe is provided to reconstitute the powdered medicine
e-filled pen)
Indication:2
• Indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for:
° Routine prophylaxis to reduce the frequency of bleeding episodes
° On-demand treatment and control of bleeding episodes
• Perioperative management of bleeding
References
1. EMA. Mounjaro Summary of Product Characteristics. 25 October 2024. Available from: https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf [Accessed 6 November 2024].
2. FDA. ALTUVIIIO® Highlights of Prescribing Information. May 2024. Available from: https://www.fda.gov/media/165594/download. [Accessed 6 November 2024].
3. FDA. TEVIMBRA® Highlights of Prescribing Information. March 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761232Orig1s000lbl.pdf [Accessed 7 November 2024].
